Stephen Inns

Dr. Stephen Inns


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2018 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
SESusanna Every-Palmer
Susanna Every-Palmer
SIStephen Inns
Stephen Inns
EGEve Grant
Eve Grant
PEPete M. Ellis
Pete M. Ellis

26 June 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
SNSophia-Louise Noble
Sophia-Louise Noble
RTRichard Tyrrell
Richard Tyrrell
TMThomas C. Mules
Thomas C. Mules
SIStephen Inns
Stephen Inns
Background and aims: Current assessments for diagnosing and monitoring eosinophilic esophagitis (EoE) are invasive, time-intensive and costly. The development of non-invasive biomarkers that are sensitive and specific for EoE is paramount. We aimed to provide a comprehensive update on the latest biomarker discovery research in EoE and discuss the current state of the field.Methods: PubMed, Web of Science, Medline and Embase were searched for studies on non-invasive biomarkers for EoE. Extracted studies were analyzed for risk of bias and relevant data was extracted, including study design, participants, information on controls, biomarker detection method, biomarkers studied, and biomarkers for which statistical significance was found.Results: Of the 239 studies identified, 37 articles met the inclusion criteria and were included in the systematic review. Across these studies, over 80 biomarkers were evaluated as potential non-invasive tools for diagnosing and monitoring EoE. While the most commonly investigated biomarker was peripheral eosinophil count (PEC), overall PEC demonstrated limited reliability. Other emerging biomarkers, including eosinophil-derived proteins (e.g., EDN, MBP-1) and cytokines (e.g., eotaxin-3), showed promise, although findings were inconsistent between studies. Esophageal-specific sampling methods, such as the Cytosponge, esophageal string test (EST), and esophageal brushings, demonstrated strong correlations with histologic eosinophil counts and disease activity, particularly through the measurement of eosinophil-associated proteins.Conclusion: Esophageal-specific sampling methods show significant promise for accurately diagnosing and monitoring EoE, particularly through eosinophil-derived biomarkers, such as eosinophil-derived neurotoxin (EDN). Furthermore, these methods were better tolerated and more cost-effective compared to endoscopy and biopsy.

24 March 2017 in Digestive Diseases
Verified
Journal Article
Closed access
EEElena Eliadou
Elena Eliadou
GKGregory Kini
Gregory Kini
JHJudy Huang
Judy Huang
ACAmy Champion
Amy Champion
SIStephen Inns
Stephen Inns
Background: No study has compared changes in quality of life (QoL) following iron therapy between anemic and non-anemic, hypoferritinemic patients. This study compares the impact of parenteral iron replacement on QoL in inflammatory bowel disease (IBD) patients with anemia, or in those with hypoferritinemia alone. Methods: Consecutive IBD patients diagnosed with anemia or hypoferritinemia were enrolled. IBD questionnaire (IBDQ) and 36-Item Short Form Survey (SF36) at diagnosis and 6 weeks post treatment were measured. Results: Ten patients with anemia and 13 with hypoferritinemia were treated with intravenous iron polymaltose. Across all patients, there was a significant improvement in median SF36 mental component score by 8.5 (p = 0.004) and median IBDQ by 12 (p = 0.02). There was a trend towards improved median SF36 physical component score by 3.2 (p = 0.6). These changes were not significantly different when comparing anemic with hypoferritinemic patients. In IBDQ, there was a trend toward greater improvement in hypoferritinemic vs. anemic patients (20 vs. 1.5, p = 0.31). Conclusions: This is the first study to show that improvements in QoL in hypoferritinemic patients are similar to those with anemia. Based on these results, patients with IBD should be offered the option of iron therapy when they are found to be hypoferritinemic, even in the absence of anemia.

2 October 2012 in Frontline Gastroenterology
Verified
Journal Article
Closed access
PDF file
SIStephen Inns
Stephen Inns
AEAnton V Emmanuel
Anton V Emmanuel
Background This study aimed to assess the dietary advice practice of UK and New Zealand (NZ) adult gastroenterologists in inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Methods A questionnaire regarding dietary advice practice was emailed or mailed to all members of the British Society of Gastroenterology (n=983) and the NZ Society of Gastroenterology (n=54). Results 363 questionnaires were returned in the UK (response rate 37%) and 51 in NZ (94%). More respondents gave specific dietary advice to more than 25% of their patients on IBS than IBD (84% vs 27% UK, 90% vs 55% NZ; p=0.001 for both) and gave advice about dietary exclusions to more than 25% of patients on IBS than IBD (61% vs 13% UK, 77% vs 14% NZ; p<0.001 for both). They were most likely to provide dietary advice to patients with small bowel Crohn's disease, difficult to control IBD, diarrhoea predominant IBS and difficult to control IBS. The majority of respondents agreed strongly or a little that dietary exclusion was effective in the treatment of IBS, compared to the minority in IBD (71% vs 39% UK, 84% vs 43% p<0.05 for both). Conclusions UK and NZ gastroenterologists give dietary advice more commonly to IBS than IBD patients. The majority of gastroenterologists have some confidence in the use of dietary exclusion in IBS, the converse is true in IBD. However, the advice given is largely empiric and mostly comprises the exclusion of fibre, dairy and wheat.

1 July 2019 in Clinical and Experimental Gastroenterology
Verified
Journal Article
Open access
PDF file
KWKavindu Weerasekera
Kavindu Weerasekera
DSDalice Sim
Dalice Sim
FCFinbarr Coughlan
Finbarr Coughlan
SIStephen Inns
Stephen Inns
Background and aim: Eosinophilic esophagitis (EoE) is an immune-mediated inflammatory condition of the esophagus. Recent literature has shown an increasing incidence of the disease. However, no epidemiological data exist regarding New Zealand rates of EoE. The disease is associated with atopy, and New Zealand’s high rate of atopic disease means the disease may be important in our population. We carried out a retrospective study to describe the incidence of EoE in the Wellington region of New Zealand, as well as key histological and clinical factors associated with the disease. Method: A search was made of laboratory and endoscopic databases in the Wellington region to identify all diagnosed cases in the five years between January 1, 2011, and December 31, 2015. Case notes were examined to determine the key demographic and clinical parameters in the cases. Incidence rates were calculated for each year, and the effects of age group and sex on the incidence rates were analyzed. Result: We found 152 cases of EoE in the Wellington region with an annual incidence of 6.95 per 100,000 person/years. We found no evidence of a significant difference in incidence rates by year in our study population. There was a significantly lower incidence rate in those aged <16 compared to those aged ≥16 (RR=0.26). Males had a higher incidence rate than females with an estimated rate ratio of 2.45 (p<0.05). Conclusion: Our results are in contrast to previous reports of increasing incidence rates and may reflect a leveling off of incidence. Further research is needed to determine whether the low incidence in our pediatric age group is due to ascertainment bias or due to a real difference in the epidemiology of EoE in NZ compared to other countries.

1 August 2020 in Clinical and Experimental Gastroenterology
Verified
Journal Article
Open access
PDF file
RHRobert Hackett
Robert Hackett
RGRichard Gearry
Richard Gearry
CHChristine Ho
Christine Ho
AMAndrew McCombie
Andrew McCombie
MMMegan Mackay
Megan Mackay
SIStephen Inns
Stephen Inns
Aim: This study audits the delivery and standards of New Zealand (NZ) inflammatory bowel disease (IBD) care against international standards, with emphasis on the IBD nursing role. Methods: Utilising international standards in IBD care, a 3 phase national multicentre survey study was performed between 2015 and 2019. We 1) evaluated the current role and practices of IBD nurses, 2) evaluated IBD service provision and identified areas for improvement, and 3) audited key aspects of IBD patient care, directly comparing nurse-led and doctor-led outpatient clinics. Results: The median duration spent in an IBD nursing role was 21 months (range 2 to 120 months) with the majority (12/15) performing two or more nursing roles. The median IBD nurse full-time equivalent (FTE) was 0.8 (range 0.2 to 1.25). The average number of hours spent undertaking IBD nursing tasks was 22.2 – a 6.8-hour shortfall compared to rostered hours. No service had a per capita IBD multidisciplinary team (MDT) FTE which met international standards. Just under two-thirds (62.5%) of departments held a regular MDT meeting. All responding services could be contacted directly by IBD patients and respond within 48 hours of contact. During 492 doctor-led and 196 nurse-led scheduled outpatient clinic visits, nurses were significantly more likely to document weight, smoking status and organise appropriate colonoscopic surveillance than doctors. Conclusion: Multiple nursing job roles resulted in rostered hours being insufficient to complete IBD specific tasks. IBD FTE did not meet international standards. The IBD care was patient-centred, encouraging direct contact from patients with prompt response. IBD nurses in NZ provide high-quality outpatient care when measured against auditable standards. As the IBD nursing role continues to develop, following the implementation of an educational framework and education programme, an increase in numbers is required in order to achieve the recommended minimum FTE per 250 000 population.